Paul Rennert
banner
pdrworld.bsky.social
Paul Rennert
@pdrworld.bsky.social
Biotech exec, pro drug developer. Amateur everything else: COOKING, ferments, preserving, charcuterie, fishing, gardening, weightlifting, BIRDER, photography, physics, literature, writer, history, DAD
A very interesting bispecific ADC highlighted today by
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
Bristol's third pivotal iza-bren study
oncologypipeline.com
August 15, 2025 at 6:03 PM
odd dynamic between clean energy needs and protecting ocean/avian ecosystems

hard to choose a side? yep...

chng.it/ThgpyJY2Pw
This campaign needs you now
Ban the over-use of single use plastics.
chng.it
July 25, 2025 at 4:27 PM
Mars, duh.
July 22, 2025 at 7:48 PM
for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...
July 22, 2025 at 11:54 AM
Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR

www.thelancet.com/journals/lan...
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex m...
www.thelancet.com
July 8, 2025 at 12:53 PM
Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...

Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
July 8, 2025 at 12:13 PM
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
July 7, 2025 at 11:39 AM
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
July 6, 2025 at 2:22 PM
tgif.
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'
15. The Wheel -} Wharf Rat - Grateful Dead - 5/7/77 Boston Garden, Boston, MA - U31DoD 2012 Edition
YouTube video by NuttyRiv3r
www.youtube.com
June 20, 2025 at 11:59 PM
June snacks
June 11, 2025 at 11:11 PM
Remarkable - Swallow-Tailed Kites are using a highly localized cicada emergence as an excuse to hang around and possibly nest in Mashpee MA, way north of their closest haunts in N.Carolina and FL #birding #birdblue
June 7, 2025 at 8:31 PM
A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky

www.astrazeneca.com/media-centre...
Acquisition of EsoBiotec completed
www.astrazeneca.com
May 20, 2025 at 2:12 PM
ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...
Novel bispecific antibodies – Part 2 – immunology, asthma and atopic dermatitis — SugarCone Biotech
In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...
sugarconebiotech.com
April 17, 2025 at 5:17 PM
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 9, 2025 at 11:11 AM
Reposted by Paul Rennert
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 8, 2025 at 8:18 PM
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 8, 2025 at 8:18 PM
Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms

Beigene news via #ApexOnco

www.oncologypipeline.com/apexonco/bei...
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
www.oncologypipeline.com
April 3, 2025 at 2:05 PM
haven't listened to this '77 very much, it's blistering

www.youtube.com/watch?v=wPgE...
Grateful Dead - Memorial Coliseum (Tuscaloosa, AL) 05/17/1977 (Complete Show)
YouTube video by Jack Straw From Wichita
www.youtube.com
April 2, 2025 at 8:54 PM
T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ...

www.aletabio.com/blog-1-1/ale...

@BioAleta
Aleta’s Novel T Cell Engagers — Aleta Biotherapeutics
By Paul Rennert Aleta’s CSO and Co-Founder Paul Rennert talks about the company’s recent announcement that their scientists created, characterized, and validated novel classes of Immune Cell Engager...
www.aletabio.com
March 25, 2025 at 1:41 PM
Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ...

www.sugarconebiotech.com/insights/ale...

proprietary technology that works just as well with CAR T engager proteins

#aletabio #bispecifics #CARTcells
Aleta’s Novel T Cell Engagers — SugarCone Biotech
Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...
www.sugarconebiotech.com
March 24, 2025 at 9:51 PM
Whoa #biotech

$CRGX implodes.
March 18, 2025 at 9:32 PM